Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Londoño MC, Riveiro-Barciela M, Ahumada A, Muñoz-Gómez R, Roget M, Devesa-Medina MJ, Serra MÁ, Navascués CA, Baliellas C, Aldamiz-Echevarría T, Gutiérrez ML, Polo-Lorduy B, Carmona I, Benlloch S, Bonet L, García-Samaniego J, Jiménez-Pérez M, Morán-Sánchez S, Castro Á, Delgado M, Gea-Rodríguez F, Martín-Granizo I, Montes ML, Morano L, Castaño MA, de Los Santos I, Laguno M, Losa JE, Montero-Alonso M, Rivero A, de Álvaro C, Manzanares A, Mallolas J, Barril G, González-Parra E, García-Buey L. Londoño MC, et al. Among authors: castro a. PLoS One. 2019 Sep 24;14(9):e0221567. doi: 10.1371/journal.pone.0221567. eCollection 2019. PLoS One. 2019. PMID: 31550267 Free PMC article.
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Alonso S, et al. Among authors: castro a. J Viral Hepat. 2017 Apr;24(4):304-311. doi: 10.1111/jvh.12648. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935168 Free article.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group. Labarga P, et al. Among authors: castro a. J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807523 Clinical Trial.
4,605 results